LONDON (Alliance News) - Midatech Pharma PLC said Wednesday it expects to meet market expectations for 2018 after increasing half-year revenue year-on-year.
For the six months to June 30, the pharmaceutical company said it expects gross product revenue of GBP5.8 million, a 16% increase on the GBP5.0 million reported for the same period last year.
The company added that two of its clinical trials for its key oncology drug candidates continue to progress well.
Midatech shares were trading down 1.8% at 28.00 pence each.


Midatech Pharma PLC - Cardiff-based R&D biotechnology company focused on improving the bio-delivery and bio-distribution of medicines - Says resolutio...


(Alliance News) - Midatech Pharma PLC on Wednesday said it has raised USD6.0 million through a private placement of 10.3 million shares at USD0.58 eac...


Midatech Pharma PLC - Cardiff-based R&D biotechnology company focused on improving the bio-delivery and bio-distribution of medicines - Says resolutio...


(Alliance News) - Midatech Pharma PLC on Wednesday said it has raised USD6.0 million through a private placement of 10.3 million shares at USD0.58 eac...


Midatech Pharma PLC - Cardiff-based R&D biotechnology company focused on improving the bio-delivery and bio-distribution of medicines - Raises gross p...


(Alliance News) - Midatech Pharma PLC on Friday said it received notice that its share price has fallen short of the minimum needed according to Nasda...


(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:


(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: